Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 6/20 | 0.45 |
| ▸ | CA2 | P00918 | 6/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7754870 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 | |
| SCHEMBL9543062 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 | |
| SCHEMBL18805935 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 | |
| SCHEMBL3406853 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 | |
| SCHEMBL23665084 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 | |
| SCHEMBL19770394 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 | |
| SCHEMBL23665088 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 | |
| SCHEMBL7753936 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 | |
| SCHEMBL22779020 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 | |
| SCHEMBL17679207 | 1.00 | FUCA1 (0.45) | FUCA1CA2CA9CA12GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115819279-B | Preparation method of bromoxynil octanoate | 青岛润农化工有限公司 | 2024-08-20 | — | — | CN | claimed |
| CN-117503721-A | Pirfenidone sustained release oral solid preparation | 越洋医药开发(广州)有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-116745430-A | Production of oligosaccharides comprising LN3 as core structure in host cells | 因比奥斯公司 | 2023-09-12 | — | — | CN | claimed |
| CN-116096912-A | Production of a mixture of neutral nonfucosylated oligosaccharides by cells | 因比奥斯公司 | 2023-05-09 | — | — | CN | claimed |
| US-6245358-B1 | FREEZE DRYING | PHARMACIA & UPJOHN S.P.A. (IT) | 2001-06-12 | — | — | US | claimed |
| EP-0574571-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYMER DERIVATIVE-BOUND ANTHRACYCLINE GLYCOSIDES AND A METHOD FOR THEIR PREPARATION | PHARMACIA & UPJOHN SPA (IT) | 1999-05-06 | — | — | EP | claimed |
| EP-0574571-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYMER DERIVATIVE-BOUND ANTHRACYCLINE GLYCOSIDES AND A METHOD FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.p.A. (IT) | 1993-12-22 | — | — | EP | claimed |
| WO-1993013804-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYMER DERIVATIVE-BOUND ANTHRACYCLINE GLYCOSIDES AND A METHOD FOR THEIR PREPARATION | FARMITALIA CARLO ERBA SRL (IT) | 1993-07-22 | — | — | WO | claimed |
| US-5037883-A | Hydroxypropylmethacrylamide polymer with peptide side chains to which are attached drugs for delivery to target cells | CESKOSLOVENSKA AKADEMIE VED (CS) | 1991-08-06 | — | — | US | claimed |
| EP-0187547-B1 | SYNTHETIC POLYMERIC DRUGS | Ceskoslovenska akademie ved (CS) | 1991-02-27 | — | — | EP | claimed |
| EP-0187547-A2 | Synthetic polymeric drugs | Ceskoslovenska akademie ved (CS) | 1986-07-16 | — | — | EP | claimed |
| CN-122055374-A | Lipid compounds and compositions for tissue-specific delivery of active substances | 韩国生命工学研究院 | 2026-05-15 | — | — | CN | disclosed |
| US-12606830-B2 | Protected antibody-drug and aptamer-drug conjugates | KOSAK KENNETH MICHAEL (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250313835-A1 | MICELLAR NANOPARTICLES AND USES THEREOF | BIORCHESTRA CO., LTD. (KR) | 2025-10-09 | — | — | US | disclosed |
| US-12428456-B2 | Peptide directed protein knockdown | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-09-30 | — | — | US | disclosed |
| EP-0401248-A1 | AFFINITY MATRICES OF MODIFIED POLYSACCHARIDE SUPPORTS | Cuno Incorporated (US) | 1990-12-12 | — | — | EP | disclosed |
| WO-1989007618-A1 | AFFINITY MATRICES OF MODIFIED POLYSACCHARIDE SUPPORTS | CUNO, INCORPORATED (US) | 1989-08-24 | — | — | WO | disclosed |
| EP-0280817-A2 | Process for the removal of basic materials from plant products | Philip Morris Products Inc. (US) | 1988-09-07 | — | — | EP | disclosed |
| US-4638816-A | Smoking compositions containing a glycosylamine flavorant additive | PHILIP MORRIS INCORPORATED (US) | 1987-01-27 | — | — | US | disclosed |
| EP-0187547-A2 | Synthetic polymeric drugs | Ceskoslovenska akademie ved (CS) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606830-B2 | Protected antibody-drug and aptamer-drug conjugates | PABPC1, PABPC4, ABCG2 | FUCA1 2579/4885CA2 2535/4885CA9 1435/4885 |
| US-20250313835-A1 | MICELLAR NANOPARTICLES AND USES THEREOF | HNRNPLL, UACA, POLRMT | FUCA1 1610/4885CA2 2771/4885CA9 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.